Non-Motor Features of Cervical Dystonia (CD)

Status Completed

Clinical Trial Summary

This study will examine the prevalence of four previously identified non-motor markers in a population of cervical dystonia patients, unaffected family members, and healthy volunteers in an attempt to identify a distinct combination of non-motor symptoms that may be indicative of disease development.

Clinical Trial Description

The primary aim of this study is to identify the prevalence of four previously identified non-motor markers - (1) spatial discrimination threshold, (2) temporal discrimination threshold, (3) vibration-induced illusion of movement, and (4) kinesthesia - in a population of cervical dystonia patients, unaffected family members, and healthy volunteers (control group). Consenting participants will receive a neurological examination performed by a movement disorders neurologist, followed by an assessment of the four non-motor symptoms.

The investigators hypothesize that a distinct combination of non-motor symptoms will be more prevalent in the CD group, and therefore this set of symptoms may be indicative of disease development. This combination will be identified through analysis of the concurrence of the non-motor features across the three groups of participants. This study will fill an important unmet need, as to the investigators' knowledge there are no published studies assessing the comorbid presentation of these four non-motor symptoms in a single cervical dystonia population. The exploration of a distinct combination of concurrent non-motor symptoms as a marker for the development of cervical dystonia will improve the ability of movement disorders neurologists to diagnose the condition.

The results of this study will facilitate the investigators' longstanding aim of improving rates of cervical dystonia diagnosis. Cervical dystonia is currently diagnosed based upon the exclusion of other movement disorders; therefore, characterization of non-motor features in cervical dystonia patients will help to refine the diagnostic criteria for this condition. This investigation will also improve understanding of the factors associated with CD. Future studies can examine the source of these associated factors in order to help understand the cause of CD, since the etiology is currently unknown. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03471923
Study type	Observational
Source	Vanderbilt University Medical Center
Contact
Status	Completed
Phase
Start date	March 26, 2018
Completion date	December 2, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05086809` - Investigation of an Updated Bone-anchored Sound Processor	N/A
Completed	`NCT05080777` - Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems	N/A
Recruiting	`NCT03222375` - SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism	N/A
Completed	`NCT03295786` - Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease	Phase 1/Phase 2
Completed	`NCT01915368` - Determining Optimal Post-Stroke Exercise (DOSE)	N/A
Completed	`NCT01922258` - Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type	Phase 3
Terminated	`NCT03270189` - Effect of the Visual Information Change in Functional Dystonia	N/A
Active, not recruiting	`NCT03911388` - HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors	Phase 1
Completed	`NCT02798406` - Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects	Phase 2
Suspended	`NCT04912115` - Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia	Phase 2
Completed	`NCT03994822` - pRESET for Occlusive Stroke Treatment	N/A
Completed	`NCT03336645` - Open-label Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Children With Status Epilepticus (Convulsive) in a Healthcare Setting in Japan	Phase 3
Completed	`NCT04283253` - Predictors of Response in Chronic Stroke	N/A
Not yet recruiting	`NCT06048523` - Prospective Cohort Study of Neurogenetic Diseases	N/A
Completed	`NCT02684825` - Detection of Silent Atrial Fibrillation aFter Ischemic StrOke	N/A
Active, not recruiting	`NCT02284126` - Topical Vancomycin for Neurosurgery Wound Prophylaxis	Phase 3
Completed	`NCT05815836` - Precision Medicine in Stroke
Completed	`NCT00739518` - Refinement and Assessment of New Magnetic Resonance Imaging Technologies for Neurological Exams	N/A
Recruiting	`NCT03678194` - Treating Depression on a Day-to-day Basis: Development of a Tool for Physicians Based on a Smartphone Application	N/A
Recruiting	`NCT04698421` - Collection of Biological Samples From Patients With Rare Neurological Diseases

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.